ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice

Journal of Lipid Research

Volumn 39, Issue 2, 1998, Pages 313-321

  Voyiaziakis, Emanuel ^a   Goldberg, Ira J ^a   Plump, Andrew S ^b   Rubin, Edward M ^c   Breslow, Jan L ^b   Huang, Li Shin ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ApoA I; ApoB; Atherosclerosis; Hypertriglyceridemia; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL LIPASE;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROGENIC DIET; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CORONARY RISK; ENZYME ACTIVATION; ENZYME DEFICIENCY; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN DEFICIENCY; LIPOPROTEIN METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; AORTIC DISEASES; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ARTERIOSCLEROSIS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY FATS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN LIPASE; MALE; MICE; MICE, TRANSGENIC;

EID: 0031910099     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Breslow, J. L. 1989. Familial disorders of high density lipoprotein metabolism. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. R. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York, NY. 1251-1266.
2. Miller, N. E. 1987. Association of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am. Heart J. 113: 589-597.
3. Miller, G. J., and N. E. Miller. 1975. Plasma-high-density-lipoprotein concentration and development of ischaemic heart disease. Lancet. 1: 16-19.
4. Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J. Clin. Invest. 66: 892-890.
5. Assmann, G., G. Schmitz, and H. B. Brewer, Jr. 1989. Familial high density lipoprotein deficiency: Tangier disease. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York, NY. 1267-1282.
6. Brunzell, J. D. 1989. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York, NY. 1165-1180.
7. Benlian, P., J. L. de Gennes, L. Foubert, H. Zhang, S. E. Gagne, and M. Hayden. 1996. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N. Engl. J. Med. 335: 848-854.
8. Badimon, J. J., L. Badimon, and V. Fuster. 1990. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85: 1234-1241.
9. Miyazaki, A., S. Sakuma, W. Morikawa, T. Takiue, F. Miake, T. Terano, M. Sakai, H. Hakamata, Y. Sakamoto, M. Natio, Y. Ruan, K. Takahashi, T. Ohta, and S. Horiuchi. 1995. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol. 155: 1882-1888.
10. Nishina, P. M., J. Wang, W. Toyofuku, F. A. Kuypers, B. Y. Ishida, and B. Paigen. 1993. Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. Lipids. 28: 599-605.
11. Rubin, E. M., R. Krauss, E. Spangler, S. Verstuyft, and S. Clift. 1991. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature. 353: 265-267.
12. Liu, A. C., R. M. Lawn, J. G. Verstuyft, and E. M. Rubin. 1994. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein [a] in transgenic mice. J. Lipid Res. 35: 2263-2267.
13. Plump, A. S., C. J. Scott, and J. L. Breslow. 1994. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA. 91: 9607-9611.
14. Paszty, C., N. Maeda, J. Verstuyft, and E. M. Rubin. 1994. Apolipoprotein A-I transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 94: 899-903.
15. Li, H., R. L. Reddick, and N. Maeda. 1993. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler. Thromb. 13: 1814-1821.
16. Plump, A. S., T. Hayek, A. Walsh, and J. L. Breslow. 1993. Diminished HDL cholesterol ester flux in apoA-I-deficient mice. Circulation. 88: 2266. (Abstr.)
17. Plump, A. S., S. K. Erickson, W. Weng, J. S. Partin, J. L. Breslow, and D. Williams. 1996. Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production. J. Clin. Invest. 97: 2660-2671.
18. Callow, M. J., L. J. Stoltzfus, R. M. Lawn, and E. M. Rubin. 1994. Expression of human apolipoprotein B and assembly of lipoprotein [a] in transgenic mice. Proc. Natl. Acad. Sci. USA. 91: 2130-2134.
19. Nikkila, E. A., M. R. Taskinen, and T. Sane. 1987. Plasma high-density lipoprotein concentration and subfraction distribution in relation to triglyceride metabolism. Am. Heart J. 113: 543-548.
20. Huang, L. S., E. Voyiaziakis, D. F. Markenson, K. A. Sokol, T. Hayek, and J. L. Breslow. 1995. ApoB gene knockout in mice results in embryonic lethality in homozygotes and neural tube defects, male infertility, and reduced HDL cholesteryl ester and apoA-I transport rates in heterozygotes. J. Clin. Invest. 96: 2152-2161.
21. Plump, A. S., S. D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J. G. Verstuyft, E. M. Rubin, and J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71: 343-353.
22. Shachter, N. S., T. Hayek, T. Leff, J. D. Smith, D. W. Rosenberg, A. Walsh, R. Ramakrishnan, I. J. Goldberg, H. N. Ginsberg, and J. L. Breslow. 1994. Overexpression of apolipoprotein C-II causes hypertriglyceridemia in transgenic mice. J. Clin. Invest. 93: 1683-1690.
23. Aalto-Setala, K., E. A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H. N. Ginsberg, and J. L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) C-III transgenic mice. J. Clin. Invest. 90: 1889-1900.
24. Baginsky, M. L., and W. V. Brown. 1976. Effects of monoolein on hydrolysis of triglyceride by lipoprotein lipase in the presence of an inhibitory apolipoprotein. Physiol. Chem. Phys. 8: 197-206.
25. Goldberg, I., J. Paterniti, D. France, G. Martinelli, and J. Cornicelli. 1986. Production and use of a monoclonal antibody to human lipoprotein lipase. Biochim. Biophys. Acta. 878: 168-176.
26. Corey, J. E., and D. B. Zilversmit. 1977. Validation of a stable emulsion for the assay of lipoprotein lipase activity. J. Lab. Clin. Med. 89: 666-674.
27. Goldberg, I. J., C. A. Scheraldi, L. K. Yacoub, U. Saxena, and C. L. Bisgaier. 1990. Lipoprotein apoC-II activation of lipoprotein lipase: modulation by apolipoprotein A-IV. J. Biol. Chem. 265: 4266-4272.
28. Saxena, U., L. D. Witte, and I. J. Goldberg. 1989. Release of endothelial cell lipoprotein lipase by plasma lipoproteins and free fatty acids. J. Biol. Chem. 262: 4349-4355.
29. Paigen, B., P. A. Holmes, D. Mitchell, and D. Albee. 1987. Comparison of atherosclerotic lesions and HDL-lipid levels in male, female and testosterone-treated female mice from strains C57BL/6, BALB/c, and C3H. Atherosclerosis. 64: 215-221.
30. Qiao, J. H., P. Z. Xie, M. C. Fishbein, J. Kreuzer, T. A. Drake, L. L. Demer, and A. J. Lusis. 1994. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler: Thromb. 14: 1480-1497.
31. Callow, M. J., J. Verstuyft, R. Tangirala, W. Palinski, and E. M. Rubin. 1995. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein [a]. J. Clin. Invest. 96: 1639-1646.
32. Purcell-Huynh, D. A., R. V. Farese, Jr., D. F. Johnson, L. M. Flynn, V. Pierotti, D. L. Newland, M. F. Linton, D. A. Sanan, and S. G. Young. 1995. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J. Clin. Invest. 95: 2246-2257.
33. Barter, P. J., and K-A. Rye. 1996. Molecular mechanisms of reverse cholesterol transport. Curr. Opin. Lipidol. 7: 82-87.
34. Tall, A. R. 1995. Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Curr. Opin. Lipidol. 6: 306-311.
35. Hughes, S. D., J. Verstuyft, S. Ighani, and E. M. Rubin. 1996. Lack of apolipoprotein A-I in human apolipoprotein B transgenic mice results in greater susceptibility to diet-induced atherosclerosis. Circulation. 96: I-633. (Abstr.)
36. Zhang, S. H., R. L. Reddick, E. Avdievich, J. K. Surles, R. G. Jones, J. B. Reynolds, S. H. Quarfordt, and N. Maeda. 1997. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J. Clin. Invest. 99: 2858-2866.
37. Blomhoff, J. P., R. Holme, J. Sauar, and E. Gjone. 1978. Familial lecithin:cholesterol acyltransferase deficiency. Further studies on plasma lipoproteins and plasma post-heparin lipase activity of a patient with normal renal function. Scand. J. Clin. Lab. Invest. Suppl. 150: 177-182.
38. Frohlich, J., R. McLeod, P. H. Pritchard, J. Fesmire, and W. McConathy. 1988. Plasma lipoprotein abnormalities in heterozygotes for familial lecithin:cholesterol acyltransferase deficiency. Metab. Clin. Exp. 37: 3-8.
39. Greten, H., R. DeGrella, G. Klose, W. Rascher, J. L. de Gennes, and E. Gjone. 1976. Measurement of two plasma triglyceride lipases by an immunochemical method: studies in patients with hypertriglyceridemia. J. Lipid Res. 17: 203-210.
40. Wang, C. S., P. Alaupovic, R. E. Gregg, and H. B. Brewer, Jr. 1987. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes. Biochim. Biophys. Acta. 920: 9-19.
41. Ginsberg, H. N., N. A. Le, I. J. Goldberg, J. C. Gibson, A. Rubinstein, P. Wang-Iverson, R. Norum, and W. V. Brown. 1986. Evidence that apolipoprotein G-III inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J. Clin. Invest. 78: 1287-1295.
42. Gustafson, A., W. J. McConathy, P. Alaupovic, M. D. Curry, and B. Persson. 1979. Identification of lipoprotein families in a variant of human plasma apolipoprotein A deficiency. Scand. J. Clin. Lab. Invest. 39: 377-387.
43. Milano carriers. Arterioscler. Thromb. 13: 521-528.